FDA Advisory Committee votes on investigational medicine metreleptin
12 December 2013 | By AstraZeneca
Advisory Committee recommends metreleptin for the treatment of paediatric and adult patients with generalised lipodystrophy...
List view / Grid view
News
Merck Statement on FDA Advisory Committee for GRASTEK® (Timothy Grass Pollen Allergen Extract), Merck’s Investigational Sublingual Allergy Immunotherapy Tablet
12 December 2013 | By Merck
GRASTEK is the proposed trade name for the company’s investigational sublingual tablet for the treatment of Timothy grass induced allergic rhinitis...
FDA advisory committee recommends the investigational SGLT2 inhibitor dapagliflozin for treatment of type 2 diabetes in adults
12 December 2013 | By AstraZeneca
Dapagliflozin is being reviewed by the FDA for use as monotherapy, and in combination with other antidiabetic agents...
Bridgepoint Development Capital to acquire Quotient Clinical
11 December 2013 | By KDM Communications
Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital for an undisclosed sum...
GSK announces £200 million investment in UK advanced manufacturing and science
11 December 2013 | By GlaxoSmithKline
Manufacturing sites in Ware, Hertfordshire and Worthing, Sussex will be upgraded with new state-of-the-art equipment...
Professor Moshe Many to leave post as Vice Chairman effective January 1, 2014, will remain a member of the board
10 December 2013 | By Teva
Amir Elstein to succeed Professor Moshe Many...
Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation
10 December 2013 | By Novo Nordisk
The reporting relates to the company’s receipt of a Complete Response Letter from the US Food and Drug Administration...
Merck advances development program for investigational Alzheimer’s Disease Therapy, MK-8931
10 December 2013 | By Merck
The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least 3 months...
New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism
10 December 2013 | By Boehringer Ingelheim
The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics...
Phase 3 data show Daiichi Sankyo’s once-daily edoxaban lowered incidence of VTE recurrence and clinically relevant bleeding
10 December 2013 | By Daiichi Sankyo Company
This analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition...
Janssen announces first-of-its-kind Drug Donation Program for HIV treatment-experienced children
9 December 2013 | By Johnson & Johnson
Sub-Saharan African Ministries of Health invited to submit expression of interest to participate in new effort donation program to be part of broader initiative to raise awareness and action...
Novartis supplies MenB vaccine, Bexsero®, to Princeton University to help protect students from potentially deadly outbreak
9 December 2013 | By Novartis
Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials...
AstraZeneca donates Brixham Environmental Laboratory to Plymouth University
9 December 2013 | By AstraZeneca
The donation of the facility and its equipment will ensure that the laboratory continues to serve scientific and research purposes...
Gilead announces pivotal phase 2 data for idelalisib in refractory indolent non-hodgkin’s lymphoma
8 December 2013 | By Gilead Sciences
In this study, single-agent treatment with idelalisib achieved an overall response rate of 57 percent with a median duration of response of 12.5 months...
Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study
6 December 2013 | By Novartis
LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma...
